Zacks: Analysts Expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to Post -$1.40 Earnings Per Share
Brokerages forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post ($1.40) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.45) and the highest estimate coming in at ($1.36). Atara Biotherapeutics reported earnings of ($1.29) per share during the same quarter last year, which would suggest a negative year over year growth rate of 8.5%. The business is expected to announce its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($5.71) per share for the current fiscal year, with EPS estimates ranging from ($5.87) to ($5.51). For the next year, analysts expect that the business will report earnings of ($5.39) per share, with EPS estimates ranging from ($5.93) to ($4.83). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.45) by ($0.15).
Shares of Atara Biotherapeutics stock traded down $0.70 during trading on Thursday, reaching $13.35. The company’s stock had a trading volume of 861,330 shares, compared to its average volume of 661,629. The firm’s 50-day moving average price is $16.10. The firm has a market capitalization of $725.20 million, a price-to-earnings ratio of -2.53 and a beta of 2.08. Atara Biotherapeutics has a 52 week low of $11.89 and a 52 week high of $43.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96.
In other news, Director Eric Dobmeier acquired 2,000 shares of the stock in a transaction dated Thursday, June 27th. The stock was bought at an average price of $19.50 per share, with a total value of $39,000.00. Following the completion of the purchase, the director now directly owns 16,000 shares of the company’s stock, valued at approximately $312,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Isaac E. Ciechanover sold 5,850 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $23.09, for a total value of $135,076.50. Following the completion of the transaction, the chief executive officer now directly owns 332,243 shares of the company’s stock, valued at approximately $7,671,490.87. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Baupost Group LLC MA increased its stake in shares of Atara Biotherapeutics by 9.7% in the second quarter. Baupost Group LLC MA now owns 7,000,000 shares of the biotechnology company’s stock valued at $140,770,000 after buying an additional 619,481 shares during the period. FMR LLC increased its position in Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after purchasing an additional 1,143,787 shares during the period. Redmile Group LLC increased its position in Atara Biotherapeutics by 1.6% during the 1st quarter. Redmile Group LLC now owns 4,485,417 shares of the biotechnology company’s stock valued at $178,295,000 after purchasing an additional 70,800 shares during the period. BlackRock Inc. increased its position in Atara Biotherapeutics by 10.2% during the 2nd quarter. BlackRock Inc. now owns 3,841,451 shares of the biotechnology company’s stock valued at $77,252,000 after purchasing an additional 357,026 shares during the period. Finally, Vanguard Group Inc. increased its position in Atara Biotherapeutics by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 3,011,596 shares of the biotechnology company’s stock valued at $60,563,000 after purchasing an additional 132,282 shares during the period.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Recommended Story: What is Considered a Good Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.